Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides

NCT04201808 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

DRUG: Tenofovir Alafenamide 25 MG

Sponsor

New Discovery LLC

Collaborators

[object Object]